Following a recent call by the World Health Organisation (WHO) for menstrual health to be recognised and addressed as a health issue as many women suffer in silence, an indigenous firm, Immunotherapy Nigeria Limited, has introduced immunocal – a bioactive biomolecules product for improving women’s health.
Immunocal is a novel class of immunotherapy designed for supplying the molecules needed by the body to repair itself of a broad range of damaged cells, resulting in hormone balancing for men and women, improving menstrual health for women, controlling autoimmune conditions, and addressing resistant infectious diseases effectively, among many other benefits.
The founder and CEO of Immunotherapy Nigeria Ltd, Lawrence Olagunju, in a statement, said: “Immunocal is the only product with the ability to influence the three most crucial biosynthesis of health simultaneously.”
Olagunju explained that with over 40 years of research, Canadian scientists identified, isolated, and packaged Immunocal, the powerful healing properties found only in mothers milk. “This is a unique formulation of 28 bioactive biomolecules that is proven with the ability to repair damaged womb and ovaries cells, restore normal, pain-free period flow, and achieve good ovulation, with a potential of obtaining pregnancy faster in women who are pregnancy challenged.”
On the potent ingredients of Immunocal, Olagunju explained that it has the ability to provide the complete nine essential and the 11 non-essential amino acids.
In the randomised use of Immunocal treatment-related reactions, a Professor of Medicine at the University of Ibadan and consultant physician at the University College Hospital, Ibadan, Adesoji Fasanmade, said, “I am delighted that Immunocal is a proven standard of care for body cells repairs and provides a significant improvement in survival for patients with diseases.
“I can testify that we give the product to many of my patients. We give it to patients who have diabetes, hypertension, and some other diseases that may want to reduce the immunity of the patient. Adding Immunocal to the primary medication of such patients makes them more equipped to compact the effect of that disease and heal faster,” he said.
